卫信康子公司琥珀酰明胶注射液临床试验获批准

财中社2025-05-07

5月7日，卫信康（603676）发布公告，近日，公司全资子公司白医制药获得国家药监局核准签发的琥珀酰明胶注射液《药物临床试验批准通知书》。该药物为注射剂，规格为500ml:20g，主要用于治疗低血容量及休克，预防低血压等。根据审批结论，该药物的临床试验申请符合药品注册要求，获准开展临床试验。截至2025年3月，公司在该药品上的累计研发投入约为573万元。根据米内网数据，2024年琥珀酰明胶注射液在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533605811?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-07 17:08","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533605811","market":"sh","top_or_hot":-1,"title":"卫信康子公司琥珀酰明胶注射液临床试验获批准","media":"财中社","content":"<div>\n<p>5月7日，卫信康（603676）发布公告，近日，公司全资子公司白医制药获得国家药监局核准签发的琥珀酰明胶注射液《药物临床试验批准通知书》。该药物为注射剂，规格为500ml:20g，主要用于治疗低血容量及休克，预防低血压等。根据审批结论，该药物的临床试验申请符合药品注册要求，获准开展临床试验。截至2025年3月，公司在该药品上的累计研发投入约为573万元。根据米内网数据，2024年琥珀酰明胶注射液在...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507174959a6d62b2e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>卫信康子公司琥珀酰明胶注射液临床试验获批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n卫信康子公司琥珀酰明胶注射液临床试验获批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-07 17:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507174959a6d62b2e&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月7日，卫信康（603676）发布公告，近日，公司全资子公司白医制药获得国家药监局核准签发的琥珀酰明胶注射液《药物临床试验批准通知书》。该药物为注射剂，规格为500ml:20g，主要用于治疗低血容量及休克，预防低血压等。根据审批结论，该药物的临床试验申请符合药品注册要求，获准开展临床试验。截至2025年3月，公司在该药品上的累计研发投入约为573万元。根据米内网数据，2024年琥珀酰明胶注射液在...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507174959a6d62b2e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507174959a6d62b2e&s=b","article_id":"2533605811","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507174959a6d62b2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533605811","pubTimestamp":1746608889,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月7日，卫信康发布公告，近日，公司全资子公司白医制药获得国家药监局核准签发的琥珀酰明胶注射液《药物临床试验批准通知书》。根据审批结论，该药物的临床试验申请符合药品注册要求，获准开展临床试验。根据米内网数据，2024年琥珀酰明胶注射液在我国城市公立医院和县级公立医院的终端销售金额为4.27亿元。2025年一季度，卫信康实现收入2.96亿元，归母净利润8454万元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603676":"卫信康","BK0239":"医药制造","BK0191":"维生素"},"translate_title":"Weixinkang subsidiary succinyl gelatin injection clinical trial approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603676":1},"content_text":"5月7日，卫信康（603676）发布公告，近日，公司全资子公司白医制药获得国家药监局核准签发的琥珀酰明胶注射液《药物临床试验批准通知书》。该药物为注射剂，规格为500ml:20g，主要用于治疗低血容量及休克，预防低血压等。根据审批结论，该药物的临床试验申请符合药品注册要求，获准开展临床试验。截至2025年3月，公司在该药品上的累计研发投入约为573万元。根据米内网数据，2024年琥珀酰明胶注射液在我国城市公立医院和县级公立医院的终端销售金额为4.27亿元。公告中提醒，药物在获得临床试验批准后，仍需完成临床试验并经审评、审批后才能生产上市，因此投资者需谨慎决策，注意风险。2025年一季度，卫信康实现收入2.96亿元，归母净利润8454万元。文章来源：财中社原标题：卫信康子公司琥珀酰明胶注射液临床试验获批准","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533605811","isCrawlerRequest":true}